Bacterial vaginosis (BV) increases your risk of contracting STIs by disrupting the vaginal environment in several concrete ways: it strips away protective acidity, degrades the mucus barrier, and triggers inflammation that makes it easier for pathogens to enter cells. A meta-analysis found that BV increases the risk of HIV acquisition by approximately 60%, and large studies have linked it to a 51% higher rate of chlamydia and a 142% higher rate of gonorrhea. These aren’t small effects, and they stem from specific biological changes that happen when the vaginal microbiome shifts out of balance.
What a Healthy Vaginal Environment Does
To understand how BV raises STI risk, it helps to know what a healthy vaginal environment actually does to keep infections out. During reproductive years, high estrogen levels ensure that vaginal cells produce glycogen, a sugar that beneficial bacteria called lactobacilli feed on. As lactobacilli break down glycogen, they produce lactic acid, which keeps the vaginal pH at 4 or below. That acidic environment is genuinely hostile to most pathogens.
Lactic acid does more than just lower pH. It can alter the surface proteins of harmful microorganisms and penetrate their cell membranes, disrupting their ability to function and survive. This gives the vagina a kind of built-in chemical defense system. Lactobacilli also produce other antimicrobial compounds and help regulate the local immune response, keeping inflammation in check so the tissue stays intact and resilient.
How BV Dismantles Those Defenses
BV happens when lactobacilli are replaced by a mix of other bacteria, primarily Gardnerella vaginalis and related species. The vaginal pH rises above 4.5, sometimes significantly. That shift alone removes one of the body’s primary barriers to infection, since many STI-causing organisms thrive at higher pH levels.
But the damage goes beyond acidity. Gardnerella vaginalis produces an enzyme called sialidase that actively breaks down the protective mucus lining the vaginal walls. This mucus layer normally acts as a physical barrier, trapping pathogens before they can reach the underlying cells. Sialidase strips away sugar molecules from mucus proteins, degrading the barrier and exposing the vulnerable tissue beneath. The enzyme activity is so characteristic of BV that sialidase levels in vaginal fluid are actually used as a diagnostic marker for the condition. Once sialidase breaks down the outer layer of mucus, it also exposes deeper components that other bacterial enzymes can attack, creating a cascading breakdown of the barrier.
Inflammation Opens the Door to Infection
BV triggers a chronic low-grade inflammatory response in vaginal and cervical tissue. The body detects the shift in bacterial populations and sends immune signaling molecules, particularly one called IL-1β, to the area. Studies that measured these inflammatory markers before and after BV treatment consistently found that IL-1β levels dropped once BV was resolved, confirming the condition itself drives the inflammation.
This inflammation is a double-edged sword. While it’s the body’s attempt to fight off harmful bacteria, it also recruits immune cells called CD4+ T cells to the vaginal lining. These are the very cells that HIV targets for entry. In the early stages of HIV acquisition in the female genital tract, the virus is picked up by CD4+ T cells or specialized immune cells located in the vaginal and cervical tissue, which then pass the virus to other CD4+ T cells. So BV essentially rolls out a welcome mat for HIV by flooding the area with the cells HIV needs to establish infection.
The Numbers: How Much Risk Increases
The HIV connection is the most extensively studied. A meta-analysis of published incidence studies found that BV increases the risk of acquiring HIV by approximately 60%. This builds on earlier estimates that placed the increase at around 40% based on fewer studies. Either way, the effect is substantial and consistent across different populations.
For bacterial STIs, a large study of over 37,000 chlamydia cases and nearly 5,000 gonorrhea cases found that having BV beforehand was associated with a 51% higher rate of chlamydia and a 142% higher rate of gonorrhea. Perhaps more striking, the study found a dose-response relationship: for every additional episode of BV a person experienced, chlamydia risk increased by 13% and gonorrhea risk by 26%. Recurrent BV compounds the problem.
BV Makes Viral Infections Harder to Clear
BV doesn’t just make it easier to catch infections. It also makes existing viral infections worse and harder for the body to resolve. For herpes (HSV-2), BV is strongly associated with increased viral shedding, meaning the virus is more frequently active on the skin’s surface even without visible sores. One study found that women with BV had 2.3 times the odds of active HSV-2 shedding compared to women without BV. More shedding means more opportunities to transmit the virus to partners, and it also means more frequent reactivation episodes for the person infected.
The pattern with HPV is equally concerning. A longitudinal study tracking women with high-risk HPV found that those who also had BV were significantly less likely to clear the virus over time. By the final year of observation, 50% of women in the BV group still had persistent high-risk HPV, compared to 24% in the group without BV. In another cohort, only 29% of women with BV achieved HPV clearance, compared to 52% of women without it. Women with lactobacillus-dominant vaginal flora consistently had the highest clearance rates. BV was also associated with a higher rate of progression toward precancerous cervical changes, with the BV group showing progression rates more than 22 percentage points higher than the comparison group.
BV and Trichomoniasis Feed Each Other
Trichomoniasis, a common parasitic STI, has a particularly close relationship with BV. In a study of HIV-positive women, 61% of those with trichomoniasis also had BV. The overall co-infection rate was 17.5%, and more than half of all participants had BV. Both conditions independently increase genital shedding of HIV, and researchers suspect they may have a synergistic effect, meaning the combination could amplify HIV transmission risk beyond what either condition causes alone.
This co-occurrence matters because both conditions can be asymptomatic. You can have BV, trichomoniasis, or both without noticeable symptoms, all while experiencing the biological changes that raise your vulnerability to other infections. BV alone is asymptomatic in many cases, which means the increased STI susceptibility can persist for weeks or months without any obvious sign that something is off.
Why Treating BV Matters for STI Prevention
Because BV works through multiple mechanisms at once, resolving it restores several layers of protection simultaneously. Inflammatory markers drop after treatment. Lactobacilli can recolonize and restore acidity. The mucus barrier has a chance to rebuild. For people with HPV, restoring a lactobacillus-dominant environment is associated with significantly better clearance rates. For those at risk of HIV exposure, reducing the concentration of target immune cells in vaginal tissue lowers the odds of acquisition.
The challenge is that BV recurs frequently. More than half of people treated for BV experience a recurrence within 12 months. Each recurrence resets the vaginal environment to a vulnerable state and, based on the dose-response data, incrementally raises STI risk. Maintaining a stable vaginal microbiome over time, not just treating individual episodes, is what provides the most consistent protection against the cascade of effects that BV sets in motion.